Assay Development Automation Drug Discovery Proteomics
Dianthus
NanoTemper Technologies, Inc
Booth: 006
Researchers in Pharma and CROs face the challenges that drug candidates and targets like PROTACs, intrinsically disordered proteins, and fragment libraries present when it comes to affinity-based screening.
The new Dianthus is a plate-based and microfluidics-free affinity-based screening platform that will offer researchers their best chance to be successful faster at these challenging screening. Dianthus wins in these applications by offering two biophysical modalities — spectral shift and TRIC — so you:
• Get results faster with less assay development
• Easily decide with confidence which hits to move forward with thanks to high-quality data
• Count on a biophysical method with the sensitivity you need to identify all the meaningful hits
• Secure results even from your less-than-perfect samples —impure, impacted by freeze and thaw cycles, or with precipitate or aggregates
Make sure to sign up to learn when the new Dianthus launches.
.png)